lipolysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
== Litigation == In 2016, the Supreme Court imposed a fine of ₹4 crore (US$420,000) on Dharampal Satyapal Limited for breaching commitments and causing delays in resolving a 2009 tax dispute. The company contested a ₹244 crore (US$25 million) tax demand related to Central Excise Duty, briefly applied to the Settlement Commission without reaching an agreement, and later faced dismissal of its petition by the Delhi High Court. DSL subsequently sought relief from the Supreme Court in 2013, securing a stay order against the tax demand.
Food irradiation – the process of exposing food and food packaging to ionizing radiation can effectively destroy organisms responsible for spoilage and foodborne illness and inhibit sprouting, extending shelf life. Commercial fruit ripening rooms using ethylene as a plant hormone. Food delivery – An order is typically made either through a restaurant or grocer's website or mobile app, or through a food ordering company. The ordered food is typically delivered in boxes or bags to the customer's doorsteps.
Singapore and Malaysia: Woodlands Train Checkpoint (Malay: Pusat Pemeriksaan Kereta Api Woodlands, Chinese: 兀兰火车关卡, Tamil: ஊட்லண்ட்ஸ் இரயில் மசாதலைச்சாவடிப): For cross-border rail passengers, Singaporean exit and Malaysian entry preclearance border controls are co-located at the Woodlands Train Checkpoint in Singapore, whilst Malaysian exit controls are located separately at Johor Bahru Sentral railway station in Malaysia. Johor Bahru – Singapore Rapid Transit System (Malay: Sistem Transit Aliran Johor Bahru–Singapura, Chinese: 新山－新加坡捷运系统, Tamil: ஜோகூர் பாரு – சிங்கப்பூர் விரைவான போக்குவரத்து அமைப்பு, RTS): The upcoming RTS connecting Singapore and Johor Bahru will feature border control preclearance both on the Singaporean side and on the Malaysian side. This will enable passengers arriving in Singapore from Malaysia or vice versa to proceed straight to their connecting transport, since the RTS will link to both the Singapore MRT system (Thomson–East Coast Line) and Johor Bahru Sentral. Unlike the preclearance systems adopted in America and Hong Kong, but similar to the United Kingdom's juxtaposed controls, this system will mitigate the need for arrival border controls on both sides of the border. Malaysia and Thailand: Padang Besar railway station (Thai: สถานีรถไฟปาดังเบซาร์, Malay: Stesen keretapi Padang Besar): The Padang Besar railway station in Padang Besar, Malaysia has co-located border control facilities for both Malaysia and Thailand. However, the station is entirely within Malaysian territory (albeit just 200 metres south of the Malaysia-Thailand border).
Secondhand smoke is tobacco smoke which affects people other than the 'active' smoker. It is made up of the exhaled smoke (15%) and mostly of smoke coming from the burning end of the cigarette, known as sidestream smoke (85%). Secondhand smoke contains more than 7000 chemicals, of which hundreds are harmful to health. Secondhand tobacco smoke includes both a gaseous and a particulate materials which, with particular hazards arising from levels of carbon monoxide and small particulates (fine particulate matter, especially PM2.5 and PM10) which get into the bronchioles and alveoles in the lung. Inhaling secondhand smoke on multiple occasions can cause asthma, pneumonia, lung cancer, and sudden infant death syndrome, among other conditions. Thirdhand smoke (THS) refers to chemicals that settle on objects and bodies indoors after smoking. Exposure to thirdhand smoke can happen even after the actual cigarette smoke is not present anymore and affect those entering the indoor environment much later. Toxic substances of THS can react with other chemicals in the air and produce new toxic chemicals that are otherwise not present in cigarettes. The only certain method to improve indoor air quality as regards secondhand smoke is to eliminate smoking indoors. Indoor e-cigarette use also increases home particulate matter concentrations.
Sources: en.wikipedia.org
Solvent assisted inlet ionization (SAII) is similar to matrix-assisted inlet ionization however the matrix is a solvent such as water, acetonitrile and methanol. This ionization technique is highly sensitive to small molecules, peptides and proteins. The analyte is dissolved in the solvent and can either be introduced to the heated inlet tube by a capillary column or directly injected into the inlet tube with a syringe or by pipetting. The capillary column is made of fused silica particles with one end submerged in the sample solvent and the other in the end of the heated inlet tube. The solvent flows through the capillary column without the use of a pump due to the pressure difference between ambient pressure and the vacuum. The temperature can vary in the inlet tube from 50 °C to 450 °C, with the lower temperature being used if the results obtained from a higher temperature are of good resolution. Solvent assisted inlet ionization can be coupled not only to liquid chromatography (LC) but also to nano LC.
Tryptophan is an important intrinsic fluorescent probe (amino acid), which can be used to estimate the nature of the microenvironment around the tryptophan residue. Most of the intrinsic fluorescence emissions of a folded protein are due to excitation of tryptophan residues.
=== Psychedelic afterglows === Psychedelics are associated with an afterglow, also known as positive subacute or post-experience effects, which may last days or even weeks after the psychedelic experience. These effects include reduction in psychopathology and increased well-being, mood, mindfulness, social functioning, spirituality, and executive functioning, and positive behavioral changes. They also include mixed changes in personality, values, attitudes, creativity, and flexibility, as well as adverse effects like headaches, sleep disturbances, and sometimes increased psychological distress. The afterglow period has been associated with changes in brain function, neuroplasticity, and immune system function. Both psychological and pharmacological effects may be involved in the afterglow phenomenon. In 1898, the English writer and intellectual Havelock Ellis reported a heightened perceptual sensitivity to "the more delicate phenomena of light and shade and color" for a prolonged period of time after his exposure to mescaline. The term "psychedelic afterglow" was first formally coined in the 1960s. Albert Hofmann, the discoverer of LSD, said the following about the aftermath of his first full LSD experience in his 1980 book LSD: My Problem Child:
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.